ENANTA PHARMACEUTICALS INC 8-K

What Happened
Enanta Pharmaceuticals, Inc. (ENTA) reported in a Form 8‑K that on June 23, 2026 the United States Court of Appeals for the Federal Circuit affirmed a December 2024 summary judgment from the U.S. District Court for the District of Massachusetts, ruling that the claims of U.S. Patent No. 11,358,953 (the “’953 Patent”) are invalid. The ’953 Patent was the basis of Enanta’s suit seeking damages against Pfizer Inc. for alleged infringement related to Paxlovid™ (nirmatrelvir tablets; ritonavir tablets). Enanta had previously filed a notice of appeal with the Federal Circuit.

Key Details

• Federal Circuit decision date: June 23, 2026.
• District court summary judgment (invalidity) originally entered: December 2024.
• Patent involved: U.S. Patent No. 11,358,953 (the “’953 Patent”).
• Case subject: Enanta sought damages for alleged infringement in the manufacture, use and sale of Pfizer’s Paxlovid.

Why It Matters
The Federal Circuit’s ruling affirms that the asserted claims of the ’953 Patent are invalid, which removes the principal legal basis for Enanta’s claimed damages from Pfizer in this matter. The Form 8‑K discloses the outcome but does not provide any financial amounts or immediate earnings impact; investors should note this materially changes the company’s litigation position and could affect the value of the related intellectual property. Enanta may disclose further developments or next steps in future filings.